Sugi Predict

Sugi Predict / Targets / BUB1

BUB1

Mitotic checkpoint serine/threonine-protein kinase BUB1 · O43683 · BUB1 on Sugi Atlas →

22,453 patent compounds predicted against BUB1, 13,743 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1518752 SCHEMBL1518752 0.55 16/20
SCHEMBL256531 SCHEMBL256531 0.49 10/20
SCHEMBL516714 SCHEMBL516714 0.49 10/20
SCHEMBL516738 SCHEMBL516738 0.47 8/20
Etriciguat Etriciguat (SCHEMBL419874) 0.51 7/20
SCHEMBL174946 SCHEMBL174946 0.54 6/20
SCHEMBL1977751 SCHEMBL1977751 0.44 6/20
SCHEMBL1651677 SCHEMBL1651677 0.42 6/20
SCHEMBL1653670 SCHEMBL1653670 0.41 6/20
SCHEMBL1518951 SCHEMBL1518951 0.67 5/20
SCHEMBL1518953 SCHEMBL1518953 0.67 5/20
SCHEMBL1518824 SCHEMBL1518824 0.55 5/20
SCHEMBL1344907 SCHEMBL1344907 0.41 5/20
SCHEMBL1220822 SCHEMBL1220822 0.40 5/20
SCHEMBL1346699 SCHEMBL1346699 0.40 5/20
SCHEMBL1218889 SCHEMBL1218889 0.35 5/20
SCHEMBL173459 SCHEMBL173459 0.53 4/20
SCHEMBL516208 SCHEMBL516208 0.51 4/20
SCHEMBL1518759 SCHEMBL1518759 0.51 4/20
SCHEMBL1518954 SCHEMBL1518954 0.48 4/20

Clinical trials — most relevant to BUB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression PHASE3RECRUITING
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer PHASE2UNKNOWN
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) PHASE1/PHASE2RECRUITING
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer PHASE2COMPLETED
Alisertib in Chemotherapy-pretreated Urothelial Cancer PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
A Clinical Study of TQB3824 in Subjects With Advanced Cancer PHASE1UNKNOWN
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia PHASE1WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors PHASE1COMPLETED
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer nanCOMPLETED
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. nanRECRUITING
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a BUB1 binder may also engage these)

ProteinNameSimilarity
O08901 — 1.000 O08901 →
Q8BMD7 — 0.997 Q8BMD7 →
PIK3C2A Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha 0.994 landscape →
Q6IVY4 — 0.993 Q6IVY4 →
Q9Z1S0 — 0.993 Q9Z1S0 →
Q8TDB6 — 0.993 Q8TDB6 →
Q9H329 — 0.992 Q9H329 →
Q5RIX9 — 0.992 Q5RIX9 →
Q92540 — 0.991 Q92540 →
Q9NRR4 — 0.991 Q9NRR4 →
Q08BS4 — 0.991 Q08BS4 →
Q9LHI7 — 0.991 Q9LHI7 →
BRPF3 Bromodomain and PHD finger-containing protein 3 0.990 landscape →
Q9NJG9 — 0.990 Q9NJG9 →
Q5RAK6 — 0.990 Q5RAK6 →
Q9C0F1 — 0.990 Q9C0F1 →
Q9D3S3 — 0.990 Q9D3S3 →
Q80TM9 — 0.990 Q80TM9 →
Q9HCH5 — 0.990 Q9HCH5 →
A4IHT0 — 0.990 A4IHT0 →
Q13415 — 0.990 Q13415 →
G5EEC5 — 0.990 G5EEC5 →
Q9NQW6 — 0.990 Q9NQW6 →
KAT6A Histone acetyltransferase KAT6A 0.990 landscape →
O13839 — 0.990 O13839 →
C5DX31 — 0.989 C5DX31 →
Q64512 — 0.989 Q64512 →
C6KRL6 — 0.989 C6KRL6 →
Q9VFG8 — 0.989 Q9VFG8 →
Q9JHS1 — 0.989 Q9JHS1 →